Big Claims, Big Promise?

December 11, 2012 | Moderna Therapeutics has billed itself the next Genentech. It's raised more than $40 milion and has attracted some big names for its Scientific Advisory Board. But questions remain about the company's RNA technology. How will the technology achieve the right therapeutic dose level? And is the mRNA approach really better than some of the long-acting proteins now on the market? Technology Review